Proactive has always been a forward looking and enthusiastic technology adopter. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. About this content Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company I ...

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon Powders Subsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT HighTech Materials with Investment Business Operations Jointly Developing Silicon Anode Products with INNOX eco-M's High-Purity Recycled Silicon Development Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - Chief Commercial Officer Melody Harris - Chief Operations Officer and President, Informatics Ali Olivo - EVP, General Counsel and Business Development Conference Call Participants Mark Massaro - BTIG Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Andrew Brackman - William Blair Tejas Savant - Morgan Stanley Mike M ...

For the quarter ended March 2024, NeoGenomics (NEO) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

NeoGenomics (NEO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.01 per share when it actually produced earnings of $0.03, delivering a surprise of 400%.Over the last four ...

Exhibit 99.1 NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Fort Myers, Florida (April 30, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights • Consolidated revenue increased 14% to $156 million • Clinical Services revenue increased 17% to $135 million • Advanced Diagnostics revenue de ...

NeoGenomics财报预测 - NeoGenomics将在2024年3月份报告的季度中，预计盈利将同比增长，但实际结果与预期相比将影响股价[1] - 分析师预计NeoGenomics将在即将发布的财报中每股亏损0.03美元，营收预计为1.4982亿美元，同比增长9.2%[4] - 分析师最近对NeoGenomics的盈利前景变得悲观，导致预期盈利与实际盈利预期相差125%[12] - NeoGenomics在过去四个季度中四次超过了盈利预期，最近一次盈利超出预期400%[15]

财务数据和关键指标变化 - 公司2023年全年收入增长16%至5.92亿美元,主要得益于渗透社区肿瘤市场、提高检测量、转向高毛利检测项目以及改善收入周期管理 [17] - 2023年全年调整后毛利为2.64亿美元,调整后毛利率为44.7% [17] - 2023年全年调整后EBITDA为正300万美元,较上年提升51.5百万美元或107% [17] 各条业务线数据和关键指标变化 - 临床服务收入为1.3亿美元,同比增长20%,主要由于检测量增加6%以及每项检测平均收入提高13% [36][37] - 高通量测序(NGS)业务占临床收入的25%以上,增长超过40% [14][37] - 高级诊断业务收入下降17%至2600万美元,主要由于2022年第四季度异常强劲以及宏观环境和优化低毛利合同的影响 [38] - 高级诊断业务毛利率同比提升368个基点 [38] 各个市场数据和关键指标变化 - 公司服务的患者数量超过60万人次 [22] - 公司在社区肿瘤医生和病理医生中的深厚关系为公司带来优势 [20] - 公司在临床检测服务的市场份额领先 [19] 公司战略和发展方向及行业竞争 - 公司2023年的四大重点包括:盈利增长核心业务、加速高级诊断、创造价值、提升人才和文化 [19] - 公司计划在2024年进一步扩大临床和高级诊断业务的销售团队 [38] - 公司正在加大研发投入,2023年推出12项新或升级的血液肿瘤和实体瘤检测产品 [25] - 公司正在整合LIMS系统,预计2024年下半年开始见效 [28][111][112] - 公司正在加强数字化转型,包括开发客户自助服务平台等 [116][117] - 公司认为FDA对实验室开发测试(LDT)的监管可能是大势所趋,公司已做好相关准备 [56][57][58][59][60] 管理层对经营环境和未来前景的评论 - 公司对2024年及以后的长期收入增长目标从7-9%提升至10%以上 [50] - 公司预计2024年收入增长10-12%至6.5-6.6亿美元,调整后EBITDA增长600-700%至2100-2400万美元 [46] - 公司认为2023年的强劲执行和财务表现为2024年持续增长奠定了基础 [47] - 公司将继续投资于销售团队优化和扩张、研发以及运营效率提升等方面 [48] 问答环节重要的提问和回答 问题1 **Alex Nowak 提问** 关于FDA对实验室开发测试(LDT)监管的问题 [55] **Chris Smith 回答** 公司已经做好相关准备,包括引进有FDA监管背景的管理团队、建立统一的质量体系等 [56][57][58][59][60] 问题2 **David Westenberg 提问** 关于公司提升长期收入增长目标的原因 [62] **Chris Smith 和 Jeff Sherman 回答** 公司对自身业务和市场的理解更加深入,看到了多方面的增长潜力,包括销售团队优化、NGS业务增长、收入周期管理等 [63][64][65][66][67] 问题3 **Puneet Souda 提问** 关于临床业务量和平均每单价的预期 [73][74] **Chris Smith 和 Jeff Sherman 回答** 公司没有具体披露临床业务量和平均每单价的预期,但会从多个方面推动包括检测量、产品组合、价格等因素的提升 [75][76][77][78][79][80]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...